logo     Print Page  Close Window

Investor Overview

KemPharm uses its LATTM platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.

 

Stock Quote
KMPH (Common Stock)
PriceChange% ChangeVolume
$3.800.000.00%0
Previous CloseToday's OpenIntraday HighIntraday Low
$3.80$0.00$3.90$3.64
Exchange: NASDAQ (US Dollar)
10/16/17 3:59 p.m. ET
Refresh quote
Recent NewsMore >>
10/04/17
KemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHD
09/20/17
KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate
09/12/17
KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources